Tenax Therapeutics, Inc. (NASDAQ:TENX – Free Report) – William Blair issued their Q3 2024 earnings per share estimates for shares of Tenax Therapeutics in a note issued to investors on Monday, September 30th. William Blair analyst M. Phipps anticipates that the specialty pharmaceutical company will post earnings of ($1.50) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($6.68) per share. William Blair also issued estimates for Tenax Therapeutics’ Q4 2024 earnings at ($1.35) EPS, FY2024 earnings at ($6.90) EPS, FY2025 earnings at ($8.33) EPS, FY2026 earnings at ($9.05) EPS and FY2027 earnings at ($9.63) EPS.
Separately, StockNews.com began coverage on Tenax Therapeutics in a report on Thursday, September 26th. They set a “sell” rating for the company.
Tenax Therapeutics Stock Performance
Shares of Tenax Therapeutics stock opened at $3.34 on Wednesday. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $61.20. The stock’s 50-day simple moving average is $3.73 and its 200 day simple moving average is $3.60.
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.99) by $0.16.
Tenax Therapeutics Company Profile
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
See Also
- Five stocks we like better than Tenax Therapeutics
- Earnings Per Share Calculator: How to Calculate EPS
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- How to Read Stock Charts for Beginners
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
